See more : Universal Cables Limited (UNIVCABLES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Hanall Biopharma Co.,Ltd (009420.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hanall Biopharma Co.,Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Formula Systems (1985) Ltd. (FORTY.TA) Income Statement Analysis – Financial Results
- Twinbird Corporation (6897.T) Income Statement Analysis – Financial Results
- Ever Harvest Group Holdings Limited (1549.HK) Income Statement Analysis – Financial Results
- North Pacific Bank,Ltd. (8524.T) Income Statement Analysis – Financial Results
- Glory Ltd. (6457.T) Income Statement Analysis – Financial Results
Hanall Biopharma Co.,Ltd (009420.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hanall.co.kr
About Hanall Biopharma Co.,Ltd
Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134.91B | 110.00B | 101.59B | 88.60B | 108.45B | 91.84B | 84.23B | 82.88B | 80.02B | 80.88B | 74.23B | 76.03B | 87.70B | 106.90B | 98.68B | 91.89B | 82.49B |
| Cost of Revenue | 59.87B | 48.02B | 41.26B | 37.95B | 45.67B | 42.81B | 41.55B | 44.38B | 43.12B | 40.84B | 42.48B | 40.57B | 43.32B | 50.75B | 48.39B | 40.26B | 35.11B |
| Gross Profit | 75.04B | 61.97B | 60.33B | 50.65B | 62.78B | 49.03B | 42.68B | 38.50B | 36.90B | 40.04B | 31.75B | 35.45B | 44.39B | 56.16B | 50.29B | 51.63B | 47.38B |
| Gross Profit Ratio | 55.62% | 56.34% | 59.39% | 57.17% | 57.89% | 53.38% | 50.67% | 46.45% | 46.11% | 49.51% | 42.77% | 46.63% | 50.61% | 52.53% | 50.96% | 56.19% | 57.44% |
| Research & Development | 23.94B | 16.50B | 10.46B | 9.32B | 10.05B | 10.54B | 9.79B | 9.00B | 6.07B | 7.79B | 9.51B | 7.92B | 7.53B | 6.54B | 6.07B | 6.28B | 4.67B |
| General & Administrative | 2.50B | 2.30B | 2.22B | 2.14B | 2.96B | 3.72B | 4.34B | 5.33B | 6.93B | 6.33B | 6.44B | 6.03B | 11.38B | 7.64B | 8.70B | 9.44B | 11.93B |
| Selling & Marketing | 23.19B | 20.93B | 18.31B | 15.23B | 13.86B | 10.09B | 6.34B | 4.73B | 6.19B | 5.15B | 8.96B | 4.59B | 8.90B | 15.94B | 12.19B | 13.65B | 8.62B |
| SG&A | 48.04B | 23.24B | 20.52B | 17.38B | 16.82B | 13.82B | 10.68B | 10.06B | 13.12B | 11.48B | 15.40B | 10.61B | 20.28B | 23.58B | 20.88B | 23.08B | 20.56B |
| Other Expenses | 0.00 | 20.73B | 19.25B | 18.02B | 18.82B | 246.42M | 338.70M | 520.86M | -602.06M | 388.32M | 909.28M | 621.93M | 37.27M | -1.35B | -255.24M | -636.57M | 173.95M |
| Operating Expenses | 71.98B | 60.47B | 50.23B | 44.72B | 45.69B | 43.55B | 39.14B | 38.22B | 41.18B | 39.23B | 44.73B | 38.52B | 51.13B | 49.31B | 46.27B | 50.48B | 49.00B |
| Cost & Expenses | 131.85B | 108.49B | 91.50B | 82.67B | 91.36B | 86.37B | 80.69B | 82.60B | 84.30B | 80.06B | 87.21B | 79.09B | 94.44B | 100.06B | 94.66B | 90.74B | 84.11B |
| Interest Income | 1.23B | 1.43B | 719.84M | 2.14B | 2.14B | 1.92B | 897.57M | 1.08B | 518.71M | 330.31M | 851.14M | 764.93M | 571.29M | 702.77M | 697.41M | 1.15B | 977.23M |
| Interest Expense | 63.86M | 21.88M | 25.48M | 16.01M | 13.75M | 600.00 | 0.00 | 0.00 | 680.08M | 988.83M | 1.37B | 2.37B | 3.47B | 4.03B | 3.43B | 2.00B | 1.53B |
| Depreciation & Amortization | 3.25B | 3.05B | 2.72B | 2.89B | 2.72B | 1.99B | 2.16B | 2.23B | 2.32B | 2.26B | 1.95B | 1.72B | 1.80B | 1.99B | 2.60B | 2.98B | 2.20B |
| EBITDA | 6.58B | 4.56B | 11.45B | 8.83B | 20.18B | 7.46B | 5.70B | 2.52B | -1.83B | -9.51B | -17.25B | 153.13M | -8.39B | 8.14B | 7.44B | 6.69B | 1.83B |
| EBITDA Ratio | 4.88% | 4.88% | 12.77% | 12.84% | 20.79% | 12.99% | 9.33% | 3.17% | -2.63% | 4.62% | -15.32% | 0.31% | -5.33% | 7.62% | 7.53% | 4.92% | 2.23% |
| Operating Income | 3.06B | 2.31B | 10.10B | 8.48B | 17.09B | 5.47B | 3.54B | 285.40M | -4.28B | 815.26M | -12.98B | -3.06B | -10.02B | 6.85B | 4.02B | 1.15B | -1.63B |
| Operating Income Ratio | 2.27% | 2.10% | 9.94% | 9.58% | 15.76% | 5.96% | 4.20% | 0.34% | -5.35% | 1.01% | -17.49% | -4.03% | -11.42% | 6.40% | 4.07% | 1.25% | -1.97% |
| Total Other Income/Expenses | 146.47M | -800.96M | -1.40B | 13.29B | -901.43M | -1.48B | -913.40M | 1.39B | -545.05M | -13.57B | -7.60B | -908.07M | -6.67B | -5.10B | -2.60B | 550.68M | -271.64M |
| Income Before Tax | 3.20B | 1.93B | 8.70B | 19.23B | 17.46B | 4.00B | 2.63B | 1.67B | -4.83B | -12.76B | -20.58B | -3.97B | -13.67B | 1.75B | 1.41B | 1.70B | -1.90B |
| Income Before Tax Ratio | 2.37% | 1.75% | 8.57% | 21.70% | 16.09% | 4.35% | 3.12% | 2.02% | -6.03% | -15.77% | -27.73% | -5.22% | -15.58% | 1.63% | 1.43% | 1.85% | -2.30% |
| Income Tax Expense | -306.08M | 1.68B | -194.05M | -539.21M | -1.72B | 696.31M | -3.19B | -352.42M | 2.25B | -99.03M | 918.61M | -1.05B | 857.88M | 1.53B | 831.30M | 529.94M | -867.33M |
| Net Income | 3.51B | 251.47M | 8.90B | 19.76B | 19.17B | 3.30B | 5.81B | 2.03B | -7.08B | -12.66B | -21.50B | -2.92B | -14.53B | 213.66M | 581.95M | 1.17B | -1.03B |
| Net Income Ratio | 2.60% | 0.23% | 8.76% | 22.31% | 17.68% | 3.59% | 6.90% | 2.44% | -8.84% | -15.65% | -28.96% | -3.84% | -16.56% | 0.20% | 0.59% | 1.27% | -1.25% |
| EPS | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 | 114.00 | 40.00 | -159.00 | -314.00 | -529.00 | -78.97 | -409.48 | 6.00 | 17.00 | 34.00 | -30.00 |
| EPS Diluted | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 | 114.00 | 40.00 | -159.00 | -314.00 | -529.00 | -78.97 | -409.48 | 6.00 | 17.00 | 34.00 | -30.00 |
| Weighted Avg Shares Out | 50.69M | 50.82M | 51.20M | 51.18M | 51.18M | 51.18M | 50.99M | 50.65M | 44.51M | 40.31M | 40.64M | 37.01M | 35.47M | 35.61M | 34.23M | 34.41M | 34.32M |
| Weighted Avg Shares Out (Dil) | 50.69M | 50.82M | 51.20M | 51.18M | 51.18M | 51.18M | 50.99M | 50.65M | 44.51M | 40.31M | 40.64M | 37.01M | 35.47M | 35.61M | 34.23M | 34.41M | 34.32M |
Source: https://incomestatements.info
Category: Stock Reports